Stevanato Group S.p.A Investor Event Transcript, Nov 18, 2026
Stevanato Group S.p.A. (STVN)
Stevanato Group expects a temporary headwind in 2027 as one of its two GLP-1 originator clients faces lower syringe demand, so it set a safe floor of low single-digit growth. The company is backfilling excess capacity with other biologic customers and expects margin expansion and a step up in free cash flow in fiscal 2027. Detailed guidance will come in March. AI summary
Conference Transcript - STVN 2026-11-18
David Windley, Analyst — Jefferies
Okay. Good afternoon. Hi, everybody. I'm Dave Windley with Jeffrey's Healthcare Equity Research in the States. I cover the pharma services and packaging supply chain players. Kind of the old gray hair in Jeffrey's research, by the way, last on the plank, or furthest out on the plank. Pleased to have Stevanotto Group here with us and the company's CEO, Franco Stevanotto, to talk to us a little bit to lead off, and then we'll go into Q&A and Giacomo Guaducci from IR here beside me. So, Franco, I'll hand it to you to lead off, please.
Franco Stevanato, CEO
Thank you, David, and thank you to Jeffrey, to host Stranato Group, for this important conference. I have assembled... Some slides in order to summarize Stevanato Group, what is our core mission, what is our path, and our future expectation. Stevanato Group is a company that is present in the pharmaceutical space since more than 75 years. It is specialized in the production of glass containers in the easy-field configuration for the pharmaceutical industry. In the last year, also, we have enlarged our product portfolio in order to serve to our pharma customers, also drug delivery system. Inside of Sternato Group, we also have one division, so-called engineering division, that is specialized first to bring the internal competitive advantage to Sternato Group because it is the division who developed the technology in-house. Also, we sell inspection machine assembly machine to the pharmaceutical company. So, practically, we build a value proposition in order to serve the best our pharmaceutical customer, our biologic customer, that they have a very strong pipeline in everything that is going to injection or self-medication. Today, also, we are market leader worldwide on cartridges, cartridges ready to fill. We are the second established player on syringes, and also we are the market leader on via ready to fill. In order to see the result in quarter three, sorry. In quarter three, we were able to deliver a group level plus 8% with organic growth. The BDS segment was able to be in double digit. The BDS segment is in double digit since more than two years, but was offset by the decline on the revenue of the engineering division compared to two last year. So, the major driver of the growth is thanks to our biologic market that is growing more and more, and we see more and more traction in what is related to our high-value product. And also, we are starting to see that our facility, our greenfield plants in Fisher, San Latina, they're starting to go in full potential. This will help us also to increase our marginality. In fact, we were able to deliver an adjusted bid-a-margin of 27% in the quarter three. What is behind Stevanato Group? Let's start from the strongest market environment. Also, we want to start to share the temporary headwind that we will face in 2027. So, Stevanato Group is serving practically the pharmaceutical industry. We have a strong market penetration into the top international customers, but also we have a very big penetration in all the other regional customers worldwide. We work with the top 25 global customers, and we have in our portfolio several hundred customers. More and more, we are focusing our strategy in what we call our high-value product solution. In particular, our EasyFill platform, our syringes, cartridges, Viya, and also we are extending our portfolio drug delivery system, because the biologic market is continuing to grow. Years ago, we had the chance to be engaged by our two historical partners for insulin into the new opportunity so-called GLP-1. In fact, we started more than five, six, seven years ago to be validated on these next syringes, and we started to serve our two originators in syringes from our plants. Practically, in 2027, we will face a temporary headwind based on the fact that one of our big clients on JLP1 will face a temporary headwind in 2027. This is why we are going to review a little bit. We have decided also to inform last week during our earning call that our guidance for the 2027 related to our growth, it will be not in high single digit or double digit. We want to set a safe floor in the low single-digit growth. Independent from this, our goal is to continue to reinforce our marginality because we have a strong mix on high-value product and we continue to reinforce our operation in Fisher and Latina. And the goal also to be very, to have a very big jump and boost in our generation of free cash flow. So what is the situation? The macro environment of the market of Biologic is growing. We are interacting with our customers. There are more than 9,000 molecules in Phase 2 and Phase 3. And through our tech center in Italy and in Boston, we are working at the early stage with our customers in order to fill the pipeline for the next year. GLP-1 is an even more attractive tailwind. It's a phenomenal therapeutic drug class. It's only less than 10% of the full penetration of the population worldwide. The target of our customer is to be penetrating approximately 1.5 billion patients in the next year. Today, in the United States, we are less than 10%. Outside of the United States, we are approximately at 2-3%. Our goal is really to be engaged and to be partnered from day one. In fact, we are equally engaged with the two originators, and we are more than We have more than 30 customers on GLP-1 today, where we have opened more than 50 programs on cartridges, say, to fill, on syringes, Nexa, and also on devices. Why? Because our goal is to replicate our strategy that we have done also in other therapeutic classes, like anesthetic, like insulin, like oncology, like heparin, to serve the originator, but also to well-spread our validation to all the other biosimilar. 2027, there will be a temporary headwind because one of the two originators is facing some temporary headwind on demand, and we were not able to backfill all the demand. It was already the good news that we have many other incremental opportunities in other fields. Let's go to the conclusion. So, Stefano Group, like I mentioned, is a 75-year-old company. We have decided to went public in 2021 to raise money in order to heavily invest in capacity for high-value product in order to build a supply chain to be more in proximity to our customers. In Europe, United States, we develop a full product portfolio of high-value products. Our revenue today around the high-value products are approximately 46%, and our trajectory is to continue to grow. We have our greenfield plants are up and running. More and more fishers deliver is arranged to our American customers. We are starting to produce vial ready-to-fill. We are starting to add, starting to ramp up the big department production for autoinjector for one of our big clients in the United States, and next year we will also add capacity for Alba. Our European plants, they are moving the track. We are starting now to activate and to do the validation of one high-speed technology for cartridges to fill with a particular patent crimping station in our plants in Latina in order to serve this growing demand for biologic. So, all our trajectories online to continue to grow in high single digit or low double digit and to reinforce our marginality and to generate the appropriate cash in order really to do a further investment in the future. Thank you.
David Windley, Analyst — Jefferies
Great. Yeah. Franco, join us over here at the table. So when we chatted in the middle of the year, The view, and albeit this may have been more of a general view, but the view was that the GLP-1 franchise was a durable double-digit growth opportunity and your engineering business was making steady progress. That obviously changed pretty materially from that point to your third-quarter earnings call. So maybe walk us through what specifically changed, what you learned, and when you learned it.
Franco Stevanato, CEO
Correct. So I need to go back a little bit, a couple of years. When we have the chance, we are honored to be engaged by our two originators in this new opportunity for JLP1, our customers that first validate in an equal way on syringes NEXA. Sorry, on syringe and Nexa, and also the second step for cartridges ready to fill, and also one of these originators has engaged us also in the drug delivery system. Two years ago, they launched the product in the market. There was one originator was a little bit ahead to the other, and the other that followed. After two years, what's happened? The situation is this, that one originator has a very strong success in particular in the United States. It builds a very strong market share position. The other has less success. This automatically has impacted what? In October of this year, when we review the new forecast for 2027, one has delivered a little bit higher. Forecast, the other have done a very strong decline for the Forecast 2027 for what is related to the syringes order for this program. We think this is a temporary headwind because these are customs that we serve both since more than 30 years. Historically, they had a very strong leadership position, and this is something that we think that it will be only temporary in 2027, David. In the meantime, what we are doing? We immediately start to backfill this capacity on excess syringes to three main areas. First, we go to some other biologic customers on syringes like 2.25 ml, 3 ml, 1.5 ml, 5 ml, in order to start to backfill with some biologic syringes where the marginality is more accretive. Second, the other originator have more strong demand because it's taking more traction in the market share, and we receive some upside in terms of order thanks to the fact that now the plants in Fisher is more up and running. We have a very strong capacity. Third, we have decided to temporarily backfill these syringes, this capacity in particular in Latina, with some non-high-value product syringes, in particular with some Eparin customers that temporarily we have decided to keep it. So all over all, we have started to have done a very good job in order to backfill this temporary drop. And on top of this, for what is related to 2027, we have incremental revenue because we have had capacity for our Alba technology in Padova. We will have incremental revenue thanks to our cartridges in Latina. We will have incremental revenue because in Germany, we are starting the new clean room for our Alina IP devices. In United States, we are ramping up more capacity for wire to fill, and we are launching this huge department for out in JETO for one big client. All overall, we will be able to backfill this. This temporary drop, and to land with a low single-digit growth in 2027. If we can add a couple of words around, again, GLP-1, we... For sure, we have certain level of headache last week. I think we injected tons of pills of momentum for the headache that this customer gave to us when they announced the forecast in October. But it's also true that the outlook of our GLP-1 customers was originator. And the other programs are very intense. Today, in the medium term, we see many other programs that are going really to spread the risk that this therapeutic class is only in the head of two players, in order to replicate the same that we see on anesthetic, on apari, on other therapeutic classes. On the top of this, we see that the biologic market is well-spread through monoclonal antibody, through rare disease, oncology product, biosimilar, MNI technology, there's many other therapeutic classes that in the medium-long term, they will even more backfill and enhance Stevanato to be back on track on high single-digit, low double-digit growth.
David Windley, Analyst — Jefferies
That's very helpful. Thank you. So in your backfilling activity, as we discussed after the quarter and as I understand it, had you not gotten this unfortunate news from your client, you would have expected to be on your... Low double-digit type trajectory of growth.
Franco Stevanato, CEO
In particular, the BDS segment, because we have the combination of the demand of nexus ranges, also this new incremental opportunity in biologic, correct? Our goal was to be in track with the result that we have done the last two years, that our average growth was more than 12% in the BDS segment, David.
David Windley, Analyst — Jefferies
Great. And then the news perhaps took out maybe around 10% of that growth, 9% to 10% of that growth, took you down to flat. You've backfilled back up to a few percentage points, something in the low single digits approach, excuse me, growth. How much of that, what's the right word, voided capacity could you still resell?
Franco Stevanato, CEO
Today, on Nexus ranges, we have backfill, but we still have free capacity in 2027, because we are starting to work with existing customers where we already have the validation. But because of the massive capacity that these customers have free up temporarily, we were not able to backfill. So we have still capacity, but it's taking time because if you already have the stability and the validation done, it's a matter of how to ramp up and where to ramp up. For example, we have decided to keep in full potential the plant from fishers because they have a strong demand, in particular, with the other originators. And we have played this backfield through the plants of Piumbinodese and Latina. Why? Because we have a higher number of validation, it was more easy to backfill. But in reality, in 2027, we have additional free capacity on Nexus range. Because of sophistication of this program, you cannot replace the customer in three to six months. Our goal is to use all the 2027 to complete this backfill. Just for your information, David, when we received this bad news in October, it was very clear. We sit with all the management team and say, guys, let's go out in 2027, what is the safe real number that we can show, and let's see how it's going to be in 2028, but removing... The temporary headwind also in 2028 in order to be sure to be able to deliver high single digit, low double digit in 2028 also if this temporary headwind will not be back in order to go with a realistic safe number.
David Windley, Analyst — Jefferies
And I believe you said around the context of the call that the impact was not a result of Say, switch to oral or a switch from single-dose to multi-dose format. Or a particular, you know, expected launch?
Franco Stevanato, CEO
No. It's only linked to the fact that they have a lot of syringes in stock and they have a lower demand compared to the expectation. And they need time to mitigate the stock. On the top of this, with these originators, we are continuing the big program for cartridges, say, to fill. And if you stay on more macro level, today we see our two originators growing rapidly on Nexus ranges, where there is an out-injector, and they are heavily investing capacity for cartridges where there is the fixed dose pen. And also, the other 30 customers in GLP-1, the reason why we have more than 50 programs, because they're biosimilar, they have a tendency to mirror the same product portfolio of the originators. So auto-injector, pen, and oral pills. But we don't see cannibalization between one to another product.
David Windley, Analyst — Jefferies
Okay. Are those 30 customers, 50 programs? I assume you already had those slotted into your capacity. Are they part of the backfill?
Franco Stevanato, CEO
Can they be part of the backfill? 30 customers, not really in 2027. There will be some, let's say, moving from phase three to early commercial product. The real backfill on Nexus ranges is doing by biologic customers. for other treatment. The other originator on excess ranges and some neparin. This GLP-1 customer biosimilar, we expect more revenue 28 and beyond, David.
David Windley, Analyst — Jefferies
Yeah. While we're, I'm going to pivot a little bit, still kind of talking about the same situation. I believe that you also identify that part of the headwind to your consolidated revenue growth 427 includes some So, rescheduling of programs or delay of programs in engineering? Correct. Talk about how that is related?
Franco Stevanato, CEO
These big clients also, they have a little bit rescheduled their CAPEX investment to us. So, we don't have yet information, but most probably they will re-phase in 2027. Correct. This is why quarter three was not at the level of our expectation or from an engineering point of view.
David Windley, Analyst — Jefferies
Okay. So that's Q3, but that... Also, is rescheduled out of 27? I mean, there's an impact, there's a revenue impact in 27 or no?
Franco Stevanato, CEO
No, no, no. Also, because anyhow, no, because in the budget expectation of engineering in 2027, we are building the budget for 2027, looking at the pipeline and order intake of all other customers not related to this one.
David Windley, Analyst — Jefferies
Okay, okay, so I misunderstood that. How should we think, then, as you think about the mix, like your high-value product sales to GLP-1s, you've talked about high-run. Customer orders are, you know, high value is priced better, but high run high value can be a little bit on the lower end. So you're perhaps losing a little bit of that. You're replacing it with a combination of biologics and standard product. What do you expect the blended margin impact of all of this to be?
Franco Stevanato, CEO
This high runner was inside of the category of high-value product, but in the lower range, more in the 40s of a gross margin. We are backfield with biologic clients, where you are more sophisticated, like 225, 5ml, 1.5ml, where the quantity is smaller. We are in the range of 10, 20, 30 million pieces, but the price is much accretive. And also the other originator is a high-value product, so this is compensated, maybe a little bit better. And then the other are upper in market on a high-value product. All combined, the mix, anyhow, is much better than to run only the high. This high runner. So this is the final goal. We have a better mix in a creative margin.
Speaker 1
So, if I may compliment on that, for the portion of the volumes that we are confident we backfilled for 2027, Margin-wise speaking, profitability speaking, this is not inferior, accretive. However, you need to consider that we still have a portion of capacity that is not backfilled, so overall the impact still should be positive. However, we'll provide detailed guidance in March. What we have said also in the last quarter earnings call, I mean, a few weeks back in the last earnings call, that on top of the low single-digit top-line growth, we do expect still to expand margins and have a step up in free cash flow generation in fiscal 2027. The extent of it will be disclosed in the next earnings call.
Franco Stevanato, CEO
Yeah, also to consider, David, that we have incremental revenue on Alba. We have just installed a high-speed line for Alba technology in Pio Mino Dese. This is in the upper part of the range of gross margin. We are starting to ramp up the high-speed line for cartridges. It's a high-value product. We are starting to ramp up Alina pen in Germany, and we bring even more in full potential the plants in Fisher. These are all elements that help really to generate a group level more positive gross margin.
David Windley, Analyst — Jefferies
Okay. Is there any element of will, as I think about the revenue mix across both segments? The it sounds like the the revenue headwind that you're absorbing from this client is all in BDS and all in high value. Is that correct?
Franco Stevanato, CEO
We on 26 we have seen some postponing postponement over also some machine also the ingenuity Okay, in 26 that is affecting 27 We don't know yet, but anyhow, the budget that we are building for 2027, that is counting the low single digit, is not considering, from a prudent point of view, this postponement of this client for engineering.
David Windley, Analyst — Jefferies
Okay, and so the, I guess what I'm getting at is if it's a low single-digit growth rate overall, will BDS and engineering grow at about the same rate, or will BDS be more affected and engineering actually grow faster?
Franco Stevanato, CEO
Now, if I'm going to answer, I will be immediately killed by the board and my CFO. Fortunately, my CFO is small, so I can take this risk to answer. So more or less, yes, it is represented, yes, the same.
David Windley, Analyst — Jefferies
Okay. So no particular mix shift there.
Franco Stevanato, CEO
Subject to march to confirm your march.
David Windley, Analyst — Jefferies
And you've... I mean, I'm obviously drilling deep on GLP-1s. You've mentioned other programs, biologics. We've generally talked about the pipeline there across multiple companies, the pipeline there being quite robust. You mentioned, you know, your go-to Nexus syringes, ready-to-fill cartridges, Alina Pen, ready-to-fill vials. How is that pipeline building, I guess? Is that continuing and to the extent that you also have any Annex 1 conversion upgrade benefits?
Franco Stevanato, CEO
On the pipeline, today our tech center, our technical team is working hard to try to, in a scientific way, approach all these 9,000 molecules in F2 and F3 and try to be validated at the early stage in order really to start The journey together with the customer at the beginning, and this is bringing very strong positive results. And next one today, where we see benefit is more traction on cartridges, rate to fill, and viral rate to fill. David. Because the clients, they prefer to go with the configuration of no two-glass contact, in particular for cartridges. And this is where we see an incremental number of program on cartridges to fill, also beyond the traditional clients.
David Windley, Analyst — Jefferies
So sorry, on Annex 1, are cartridges ready to fill?
Franco Stevanato, CEO
Annex 1 is helping to push more adoption of easy fill cartridges and easy fill via.
David Windley, Analyst — Jefferies
Okay, okay. Are we? I think we're at time. I'll call it at time there. Thanks to the audience for your attention and for your attendance at our conference, and thank you to the Stevanotto team for being here. Thank you.